Skip to main content
OpenTrials
Completed

NCT Number: NCT07543900

Immersive Virtual Reality and Exercise Programs in Multiple Sclerosis

TITLE: Immersive Virtual Reality and Exercise Programs in Multiple Sclerosis

INTRODUCTION: Multiple sclerosis (MS) is a chronic neuroimmunological and degenerative disease characterized by demyelination within the central nervous system. Its clinical course involves motor impairment, sensory disturbances, cognitive dysfunction, and a progressive decline in functional independence. MS is one of the leading causes of non-traumatic disability in young adults. This highlights the considerable impact of the disease, both in terms of healthcare burden and healthcare expenditure. Within this context, therapeutic exercise has evolved from being considered potentially harmful to being recognized as a safe and effective intervention capable of improving gait, balance, cardiorespiratory fitness, fatigue, and quality of life in people with MS. A model has been proposed for prescribing and progressing exercise at different stages of MS: passive range-of-motion exercises designed for patients with the most severe symptoms, a second stage incorporating active muscle-strengthening exercises, and finally, integrated exercise programs that incorporate strength, endurance, balance, and coordination training. Evidence from systematic reviews and meta-analyses shows that structured exercise (including high-intensity protocols when performed under supervision) is safe and can improve functional outcomes. Our ExeRVIEM III project (Effects of a Physiotherapy Program With High-Intensity Exercise and Immersive Virtual Reality in Multiple Sclerosis: Randomized Controlled Trial) represents a novel strategy to facilitate rehabilitation exercise programs using head-mounted virtual reality displays.

HYPOTHESIS: The ExeRVIEM III project, based on training physical function in people with MS, is feasible and safe, and could have a potential clinical impact in the motor and cognitive domains, as well as applicability in community settings, such as patient associations.

GENERAL OBJECTIVES:

1.1 To design and implement an ExeRVIEM III exercise program/protocol for people with MS.

1.2 To evaluate the feasibility and safety of the high-intensity virtual reality exercise program.

SPECIFIC OBJECTIVES:

2.1 To analyze the possible changes in disability, functional variables, cognitive domains and biomarkers in the short and medium term in people who attend a patient association and carry out the ExeRVIEM III exercise program/protocol for people with MS.

METHODOLOGY: A randomized controlled trial with two arms (experimental group and control group. The study will be conducted at the ACEM patient association (Santiago de Compostela, Spain). The intervention will consist of an 6-month supervised virtual physiotherapy program, with two weekly sessions on alternate days, in addition to the standard rehabilitation prescribed by the ACEM clinical team (physiotherapy, occupational therapy, and cognitive training sessions). An inmersive virtual reality (IVR) body combat exercise videogame will be used, administered via a virtual reality headset. In accordance with clinical guidelines for IVR, sessions will be intentionally brief (10 minutes) to minimize cybersickness and excessive fatigue. Assessments will be conducted at baseline (week 0) and immediately after the intervention (week 24). Demographic and clinical data will also be collected, including sex, age, comorbidities, disease duration, MS subtype, and pharmacological treatment. Assessments will be conducted at the patient association and in the Neurology Department of the referral hospital. Physical capacities assessments will be performed at the patient association supervising by physiotherapist, while the remaining assessments will be completed at the hospital by a neurologist specializing in MS (with blinding). The content of the assessments will be:

Patient characteristics: an ad hoc registration form that will include data on age, sex, years since diagnosis, MS subtype, and pharmacological treatment.

Feasibility: Number of virtual sessions attended by each participant (adherence rate via registration sheet). Rate Perceived Effort using the modified Borg scale, which measures the level of perceived exertion on a scale of 0 to 10 from no effort to maximum effort.

Safety: adverse events (side effects related to virtual reality exposure) using the Simulator Sickness Questionnaire (SSQ).

Level o disability: using the Expanded Disability Status Scale (EDSS). Gait will be evaluated using the 25Foot Walk Test (25FWT) and Timed Up and Go test Strengh with a hand dynamometer and the Five times to Sit and Stand test (FSST) Manual dexterity will be assessed using by 9-Hole Peg Test (9HPT). Cognitive domains evaluated by the Symbol Digit Modalities Test (SDMT) Axonal injury biomarker evaluated by Neurofilament light chain (sNfL) concentrations

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Vigo

Vigo, Pontevedra, 36316, Spain

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • ≥18 years of age.
  • Confirmed diagnosis of MS.
  • Stable disease with no relapse in the previous 6 weeks.
  • Patients who will be take follow up by a neurologist at the referall hospital and will be members of AVEMPO.
  • Ability to perform moderate exercise.
  • Capacity to provide informed consent.

Exclusion criteria

  • Comorbidities that hinder the development of the VR program
  • Visual or vestibular impairment that would contraindicate VR use.
  • Recent changes in disease modifying therapy.

Treatment and study plan

Virtual exercise based program

Other

The intervention will consist of a supervised virtual rehabilitation program delivered over 8 weeks, with two sessions per week on alternating days, in addition to the standard rehabilitation prescribed by the AVEMPO clinical team (physiotherapy, occupational therapy and cognitive training sessions). An Immersive Virtual Reality boxing-based exergame executed through a VR headset will be used.

Primary outcomes

  1. Adverse events linked to virtual reality exposure assessed by the Simulator Sickness Questionnaire (SSQ).

    Time frame: Week 8

    SSQ assess the IVR exposure by evaluating potential associated symptoms in three broad domains: 1. oculomotor symptoms; 2. disorientation; 3. nausea. Each item is rated on a four-point scale (0 = feel nothing; 1 = a little; 2 = moderately; and 3 = very much) and the total score (maximum of 48 points) is the sum of the scores of the three subscales.

  2. Usability of the virtual tool assessed by System Usability Scale (SUS).

    Time frame: Week 8

    SUS consists of ten questions on a Likert-type scale. Each question is scored from 1 to 5 based on the degree of agreement or disagreement with each statement, where 5 means strongly agree and 1 means strongly disagree. The algorithm resulting from these responses generates a maximum score of 100 points.

  3. Number of virtual sessions attended by each participant

    Time frame: up to 8 weeks

    Adherence rate via registration sheet

  4. Rate perceived effort (RPE) evaluated by the modified Borg scale.

    Time frame: up to 8 weeks

    The modified Borg scale and which measures the RPE on a scale of 0-10 from no exertion (0) to the greatest possible exertion (10).

Secondary outcomes

  1. Level of disability using the Expanded Disability Status Scale (EDSS)

    Time frame: Baseline

    EDSS quantifies MS related disability on a scale from 0 (normal neurological exa-mination) to 10 (MS related death). Lower scores indicate less disability and generally, and a change of between 0.5 and 1.0 points on the EDSS scale is considered clinically significant, indicating actual progression or improvement in disability

  2. Level of disability using the Expanded Disability Status Scale (EDSS)

    Time frame: Week 8

    EDSS quantifies MS related disability on a scale from 0 (normal neurological exa-mination) to 10 (MS related death). Lower scores indicate less disability and generally, and a change of between 0.5 and 1.0 points on the EDSS scale is considered clinically significant, indicating actual progression or improvement in disability

  3. Gait evaluated by 25Foot Walk Test (25FWT)

    Time frame: Baseline

    25FWT assesses walking speed over 25 feet; shorter times reflect better gait capacity. The 25FWT is a validated, reliable measure accepted by regulatory consortia (MSOAC), predictive of disability progression, where a change greater than 20% in the time taken to walk 25 feet (7.6 meters) is considered relevant to the patient's daily life, indicating a real improvement or deterioration of their functional capacity, beyond the natural variability of the test.

  4. Gait evaluated by 25Foot Walk Test (25FWT)

    Time frame: Week 8

    25FWT assesses walking speed over 25 feet; shorter times reflect better gait capacity. The 25FWT is a validated, reliable measure accepted by regulatory consortia (MSOAC), predictive of disability progression, where a change greater than 20% in the time taken to walk 25 feet (7.6 meters) is considered relevant to the patient's daily life, indicating a real improvement or deterioration of their functional capacity, beyond the natural variability of the test.

  5. Manual dexterity assessed by 9-Hole Peg Test (9HPT)

    Time frame: Baseline

    9HPT (right and left) evaluates fine manual dexterity. Lower times indicate better performance. Reductions of approximately 20% are often considered clinically meaningful, particularly in progressive MS phenotypes. Often in clinical studies, a change of 2 seconds or more in the average test execution time is considered clinically relevant, indicating an impairment in manual dexterity and fine motor function

  6. Manual dexterity assessed by 9-Hole Peg Test (9HPT)

    Time frame: Week 8

    9HPT (right and left) evaluates fine manual dexterity. Lower times indicate better performance. Reductions of approximately 20% are often considered clinically meaningful, particularly in progressive MS phenotypes. Often in clinical studies, a change of 2 seconds or more in the average test execution time is considered clinically relevant, indicating an impairment in manual dexterity and fine motor function

  7. Cognitive domains evaluated by the Symbol Digit Modalities Test (SDMT)

    Time frame: Baseline

    SDMT assesses cognitive processing speed; higher scores indicate better performance. The SDMT is highly sensitive to cognitive impairment in MS and a variation of 4 to 5 points (or a change of at least 10% from baseline) is generally considered to indicate a real and clinically relevant change in the patient's cognitive performance

  8. Cognitive domains evaluated by the Symbol Digit Modalities Test (SDMT)

    Time frame: Week 8

    SDMT assesses cognitive processing speed; higher scores indicate better performance. The SDMT is highly sensitive to cognitive impairment in MS and a variation of 4 to 5 points (or a change of at least 10% from baseline) is generally considered to indicate a real and clinically relevant change in the patient's cognitive performance

  9. Axonal injury biomarker evaluated by Neurofilament light chain (sNfL) concentrations

    Time frame: Baseline

    sNfL expressed in serum (pg/mL) evaluates disease progression. Lower levels suggest reduced neuroaxonal damage and may reflect decreased disease activity. In this study, it was performed using an automated assay for measuring sNfL (Fujirebio).

  10. Axonal injury biomarker evaluated by Neurofilament light chain (sNfL) concentrations

    Time frame: Week 8

    sNfL expressed in serum (pg/mL) evaluates disease progression. Lower levels suggest reduced neuroaxonal damage and may reflect decreased disease activity. In this study, it was performed using an automated assay for measuring sNfL (Fujirebio).

Sponsors and collaborators

Lead sponsor

University of Vigo

Other

Collaborators

  • Asociación Viguesa de Esclerosis Múltiple de Pontevedra
  • Complejo Hospitalario Universitario de Santiago
  • Hospital Álvaro Cunqueiro

Registry information

Official study title

Benefits of a High-Intensity Exercise Program With Immersive Virtual Reality in Multiple Sclerosis: Exploratory Study

Acronym: ExeRVIEM II

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Apr 22, 2026
Registry last updated
Jul 24, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.